252 related articles for article (PubMed ID: 25605352)
1. Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum.
Stickles AM; de Almeida MJ; Morrisey JM; Sheridan KA; Forquer IP; Nilsen A; Winter RW; Burrows JN; Fidock DA; Vaidya AB; Riscoe MK
Antimicrob Agents Chemother; 2015 Apr; 59(4):1977-82. PubMed ID: 25605352
[TBL] [Abstract][Full Text] [Related]
2. Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome bc
McConnell EV; Bruzual I; Pou S; Winter R; Dodean RA; Smilkstein MJ; Krollenbrock A; Nilsen A; Zakharov LN; Riscoe MK; Doggett JS
ACS Infect Dis; 2018 Nov; 4(11):1574-1584. PubMed ID: 30117728
[TBL] [Abstract][Full Text] [Related]
3. Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria.
Stickles AM; Smilkstein MJ; Morrisey JM; Li Y; Forquer IP; Kelly JX; Pou S; Winter RW; Nilsen A; Vaidya AB; Riscoe MK
Antimicrob Agents Chemother; 2016 Aug; 60(8):4853-9. PubMed ID: 27270285
[TBL] [Abstract][Full Text] [Related]
4. The antimalarial compound ELQ-400 is an unusual inhibitor of the bc
Song Z; Iorga BI; Mounkoro P; Fisher N; Meunier B
FEBS Lett; 2018 Apr; 592(8):1346-1356. PubMed ID: 29574797
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Ubiquinol-Reduction (Q
Amporndanai K; Pinthong N; O'Neill PM; Hong WD; Amewu RK; Pidathala C; Berry NG; Leung SC; Ward SA; Biagini GA; Hasnain SS; Antonyuk SV
Biology (Basel); 2022 Jul; 11(8):. PubMed ID: 35892964
[TBL] [Abstract][Full Text] [Related]
6. 7-
Nguyen W; Dans MG; Currie I; Awalt JK; Bailey BL; Lumb C; Ngo A; Favuzza P; Palandri J; Ramesh S; Penington J; Jarman KE; Mukherjee P; Chakraborty A; Maier AG; van Dooren GG; Papenfuss T; Wittlin S; Churchyard A; Baum J; Winzeler EA; Baud D; Brand S; Jackson PF; Cowman AF; Sleebs BE
ACS Infect Dis; 2023 Mar; 9(3):668-691. PubMed ID: 36853190
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy.
Stickles AM; Ting LM; Morrisey JM; Li Y; Mather MW; Meermeier E; Pershing AM; Forquer IP; Miley GP; Pou S; Winter RW; Hinrichs DJ; Kelly JX; Kim K; Vaidya AB; Riscoe MK; Nilsen A
Am J Trop Med Hyg; 2015 Jun; 92(6):1195-201. PubMed ID: 25918204
[TBL] [Abstract][Full Text] [Related]
8. Direct evidence for the atovaquone action on the Plasmodium cytochrome bc1 complex.
Siregar JE; Kurisu G; Kobayashi T; Matsuzaki M; Sakamoto K; Mi-ichi F; Watanabe Y; Hirai M; Matsuoka H; Syafruddin D; Marzuki S; Kita K
Parasitol Int; 2015 Jun; 64(3):295-300. PubMed ID: 25264100
[TBL] [Abstract][Full Text] [Related]
9. Antimalarial quinolones: synthesis, potency, and mechanistic studies.
Winter RW; Kelly JX; Smilkstein MJ; Dodean R; Hinrichs D; Riscoe MK
Exp Parasitol; 2008 Apr; 118(4):487-97. PubMed ID: 18082162
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages.
Ke H; Ganesan SM; Dass S; Morrisey JM; Pou S; Nilsen A; Riscoe MK; Mather MW; Vaidya AB
PLoS One; 2019; 14(4):e0214023. PubMed ID: 30964863
[TBL] [Abstract][Full Text] [Related]
11. HDQ, a potent inhibitor of Plasmodium falciparum proliferation, binds to the quinone reduction site of the cytochrome bc1 complex.
Vallières C; Fisher N; Antoine T; Al-Helal M; Stocks P; Berry NG; Lawrenson AS; Ward SA; O'Neill PM; Biagini GA; Meunier B
Antimicrob Agents Chemother; 2012 Jul; 56(7):3739-47. PubMed ID: 22547613
[TBL] [Abstract][Full Text] [Related]
12. The cytochrome b lysine 329 residue is critical for ubihydroquinone oxidation and proton release at the Q
Francia F; Khalfaoui-Hassani B; Lanciano P; Musiani F; Noodleman L; Venturoli G; Daldal F
Biochim Biophys Acta Bioenerg; 2019 Feb; 1860(2):167-179. PubMed ID: 30550726
[TBL] [Abstract][Full Text] [Related]
13. Reconstructing the Qo site of Plasmodium falciparum bc 1 complex in the yeast enzyme.
Vallières C; Fisher N; Meunier B
PLoS One; 2013; 8(8):e71726. PubMed ID: 23951230
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome bc1 complex [2Fe-2S] cluster and its interaction with ubiquinone and ubihydroquinone at the Qo site: a double-occupancy Qo site model.
Ding H; Robertson DE; Daldal F; Dutton PL
Biochemistry; 1992 Mar; 31(12):3144-58. PubMed ID: 1313287
[TBL] [Abstract][Full Text] [Related]
15. Genetic Evidence for Cytochrome b Qi Site Inhibition by 4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii.
Alday PH; Bruzual I; Nilsen A; Pou S; Winter R; Ben Mamoun C; Riscoe MK; Doggett JS
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919897
[TBL] [Abstract][Full Text] [Related]
16. Understanding the mechanism of atovaquone drug resistance in Plasmodium falciparum cytochrome b mutation Y268S using computational methods.
Akhoon BA; Singh KP; Varshney M; Gupta SK; Shukla Y; Gupta SK
PLoS One; 2014; 9(10):e110041. PubMed ID: 25334024
[TBL] [Abstract][Full Text] [Related]
17. Novel Endochin-Like Quinolones Exhibit Potent
van Schalkwyk DA; Riscoe MK; Pou S; Winter RW; Nilsen A; Duffey M; Moon RW; Sutherland CJ
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094134
[TBL] [Abstract][Full Text] [Related]
18. Selection of
Lane KD; Mu J; Lu J; Windle ST; Liu A; Sun PD; Wellems TE
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6285-6290. PubMed ID: 29844160
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action.
Birth D; Kao WC; Hunte C
Nat Commun; 2014 Jun; 5():4029. PubMed ID: 24893593
[TBL] [Abstract][Full Text] [Related]
20. Saccharomyces cerevisiae-based mutational analysis of the bc1 complex Qo site residue 279 to study the trade-off between atovaquone resistance and function.
Song Z; Clain J; Iorga BI; Yi Z; Fisher N; Meunier B
Antimicrob Agents Chemother; 2015 Jul; 59(7):4053-8. PubMed ID: 25918152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
